Proteomics in gastrointestinal cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Ebert, M P A ^a   Yu, J ^b   Lordick, F ^a   Rocken C ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DEAD BOX PROTEIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PROTEOME; TUMOR MARKER; TYROSINE KINASE RECEPTOR;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER GENETICS; CANCER LOCALIZATION; CANCER SCREENING; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; GENE IDENTIFICATION; GENOME ANALYSIS; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PANCREAS CANCER; PANCREAS JUICE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GASTROINTESTINAL NEOPLASMS; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 33749597693     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl269     Document Type: Review

References (45)

1. Boyle P, Autier P, Bartelink H et al. European Code Against Cancer and scientific justification: Third version (2003). Ann Oncol 2003; 14: 973-1005.
2. Boyle P, d'Onofrio A, Maisonneuve P et al. Measuring progress against cancer in Europe: Has the 15% decline targeted for 2000 come about? Ann Oncol 2003; 14: 1312-1325.
3. Gridelli C, Aapro M, Ardizzoni A et al. Treatment of advanced non-small-cell lung cancer in the elderly: Results of an international expert panel. J Clin Oncol 2005; 23: 3125-3137.
4. Bonelli L. Colorectal carcinoma: Is screening possible? Tech Coloproctol 2004; 8 (Suppl 2): S267-s272.
5. Crawford ED. PSA testing: What is the use? Lancet 2005; 365: 1447-1449.
6. Bast RC, Jr, Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-1878.
7. Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004; 127: S104-S107.
8. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
9. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
10. Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-867.
11. Anderson NL, Polanski M, Pieper R et al. The human plasma proteome: A non-redundant list developed by combination of four separate sources. Mol Cell Proteomics 2004; 3: 311-326.
12. Baak JP, Path FR, Hermsen MA et al. Genomics and proteomics in cancer. Eur J Cancer 2003; 39: 1199-1215.
13. Pieper R, Gatlin CL, Makusky AJ et al. The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003; 3: 1345-1364.
14. Espina V, Dettloff KA, Cowherd S et al. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther 2004; 4: 83-93.
15. Rosenblatt KP, Bryant-Greenwood P, Killian JK et al. Serum Proteomics in Cancer Diagnosis and Management. Annu Rev Med 2004; 55: 97-112.
16. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003; 3: 267-275.
17. Verma M, Kagan J, Sidransky D et al. Proteomic analysis of cancer-cell mitochondria. Nat Rev Cancer 2003; 3: 789-795.
18. Wulfkuhle JD, Paweletz CP, Steeg PS et al. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol 2003; 532: 59-68.
19. Gygi SP, Rist B, Gerber SA et al. Quantitative anatysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999; 17: 994-999.
20. Gronborg M, Kristiansen TZ, Iwahori A et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomics approach. Mol Cell Proteomics 2006; 5: 157-171.
21. Zhang X, Leung SM, Morris CR et al. Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech 2004; 15: 167-175.
22. Katz MH, Savides TJ, Moossa AR et al. An evidence-based approach to the diagnosis and staging of pancreatic cancer. Pancreatology 2005; 5: 576-590.
23. Takhar AS, Palaniappan P, Dhingsa R et al. Recent developments in diagnosis of pancreatic cancer. Br Med J 2004; 329: 668-673.
24. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 2005; 54 (Suppl 5): V1-16.
25. Bhattacharyya S, Siegel ER, Petersen GM et al. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasla 2004; 6: 674-686.
26. Koopmann J, Zhang Z, White N et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 860-868.
27. Xia Q, Kong XT, Zhang GA et al. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun 2005; 330: 526-532.
28. Yu Y, Chen S, Wang LS et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 2005; 68: 79-86.
29. Yu KH, Rustgi AK, Blair IA. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Prateome Res 2005; 4: 1742-1751.
30. Rosty C, Christa L, Kuzdzal S et al. Identification of hopatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002; 62: 1868-1875.
31. Gronborg M, Bunkenborg J, Kristiansen TZ et al. Comprehensive proteomic analysis of human pancreatic juice. J Prateome Res 2004; 3: 1042-1055.
32. Chen R, Yi EC, Donohoe S et al. Pancreatic cancer proteome: The proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005; 129: 1187-1197.
33. Shekouh AR, Thompson CC, Prime W et al. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 2003; 3: 1988-2001.
34. Ebert MP, Malfertheiner P. Pathogenesis of sporadic and familial gastric cancer: Implications for clinical management and cancer prevention. Aliment Pharmacol Ther 2002; 16: 1059-1066.
35. Ebert MP, Krüger S, Fogeron ML et al. Overexpression of cathepsin B in gastric cancer idenitified by proteome analysis. Proteomics 2005; 5: 1693-1704.
36. Ryu JW, Kim HJ, Lee YS et al. The proteomics approach to find biomarkers in gastric cancer. J Korean Med Sci 2003; 18: 505-509.
37. He OY, Cheung YH, Leung SY et al. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 2004: 4: 3276-3287.
38. Nishigaki R, Osaki M, Hiratsuka M et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 2005; 5: 3205-3213.
39. Melle C, Ernst G, Schimmel B et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J Proteome Res 2005; 4: 1799-1804.
40. Lee K, Kye M, Jang JS et al. Proteomic analysis revealed a strong association of a high level of alpha1 -antitrypsin in gastric juice with gastric cancer. Proteomics 2004; 4: 3343-3352.
41. Juan HF, Chen JH, Hsu WT et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: From mouse to human. Proteomics 2004; 4: 2766-2775.
42. Ebert MP, Meuer J, Wiemer JC et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res 2004; 3: 1261-1266.
43. Ebert MP, Lamer S, Meuer J et al. Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. J Proteome Res 2005; 4: 586-590.
44. Albrethsen J, Bogebo R, Gammeltoft S et al. Upregulated expression of human neurtrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: A biomarker study. BMC Cancer 2005; 5: 8.
45. Melle C, Ernst G, Schimmel B et al. Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 2005; 129: 66-73.